AXM Pharma, Inc.

AXM Pharma, Inc.

AXMP
AXM Pharma, Inc.US flagOther OTC
0.00
USD
+0.00
- -
40,860.00Market Cap
No data availableFinancial data will appear here once available

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Company Description

APIChatGPT
CEO
Linda L. Forster
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Address
30 Wall Street Las Vegas United States of America
IPO Date
Oct 15, 2018
Business
AXM Pharma, Inc. is a pharmaceutical company primarily engaged in the manufacture, marketing, and distribution of proprietary and generic pharmaceutical products, including injectables, capsules, tablets, liquids, medicated skin products, complete lice treatment kits, cranberry tablets, chest congestion relief formulations, lice killing shampoo, and ear wax removal aids. The company operates mainly in the People's Republic of China and other international markets. Founded on June 24, 1999, AXM Pharma is headquartered in New York, New York, and conducts business through its wholly owned subsidiary Werke Pharmaceuticals, Inc., which fully owns Shenyang Tianwei Werke Pharmaceutical Co. AXM Pharma recently underwent major strategic changes including a change in ownership and leadership in 2018, when Emmanuel Neossi acquired 70% control of the company and was appointed Chairman, reflecting a strategic focus on vertical integration within key agribusiness sectors, especially the global cocoa market, which aligns with broader diversification efforts outside traditional pharmaceutical operations. The company continues expanding its product portfolio and market presence, emphasizing growth in pharmaceutical manufacturing and distribution within China and internationally. This includes recent operational shifts to meet evolving regulatory standards such as Chinese Good Manufacturing Practice (cGMP) compliance and growing demand for over-the-counter and prescription drugs. AXM Pharma's product offerings and strategic realignments position it as a diversified pharmaceutical entity with cross-industry interests and expansion initiatives across global markets.